MX2022003010A - Tratamiento de la emr mediante cambio de terapia. - Google Patents
Tratamiento de la emr mediante cambio de terapia.Info
- Publication number
- MX2022003010A MX2022003010A MX2022003010A MX2022003010A MX2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A MX 2022003010 A MX2022003010 A MX 2022003010A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- therapy
- emr
- change
- ofatumumab
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196789 | 2019-09-11 | ||
| EP20154736 | 2020-01-30 | ||
| PCT/EP2020/075332 WO2021048280A1 (en) | 2019-09-11 | 2020-09-10 | Treatment of rms by switching therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003010A true MX2022003010A (es) | 2022-06-02 |
Family
ID=72709332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003010A MX2022003010A (es) | 2019-09-11 | 2020-09-10 | Tratamiento de la emr mediante cambio de terapia. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220298253A1 (https=) |
| EP (2) | EP4230655A3 (https=) |
| JP (2) | JP7794735B2 (https=) |
| KR (1) | KR20220062025A (https=) |
| CN (3) | CN118436777A (https=) |
| AU (1) | AU2020344154A1 (https=) |
| CA (1) | CA3150947A1 (https=) |
| DK (1) | DK3864053T3 (https=) |
| ES (1) | ES2957112T3 (https=) |
| FI (1) | FI3864053T3 (https=) |
| IL (1) | IL290619A (https=) |
| LT (1) | LT3864053T (https=) |
| MX (1) | MX2022003010A (https=) |
| SI (1) | SI3864053T1 (https=) |
| WO (1) | WO2021048280A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120053638A (zh) | 2016-08-15 | 2025-05-30 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| MX2022003030A (es) * | 2019-09-11 | 2022-04-07 | Novartis Ag | Tratamiento de afecciones distintas de la esclerosis multiple en pacientes tratados con ofatumumab. |
| US20230151106A1 (en) * | 2020-04-09 | 2023-05-18 | Novartis Ag | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG |
| US20240228647A1 (en) * | 2021-04-14 | 2024-07-11 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| EA201692180A1 (ru) * | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| CN120053638A (zh) | 2016-08-15 | 2025-05-30 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
-
2020
- 2020-09-10 ES ES20785440T patent/ES2957112T3/es active Active
- 2020-09-10 JP JP2022515966A patent/JP7794735B2/ja active Active
- 2020-09-10 LT LTEPPCT/EP2020/075332T patent/LT3864053T/lt unknown
- 2020-09-10 US US17/753,632 patent/US20220298253A1/en active Pending
- 2020-09-10 WO PCT/EP2020/075332 patent/WO2021048280A1/en not_active Ceased
- 2020-09-10 MX MX2022003010A patent/MX2022003010A/es unknown
- 2020-09-10 DK DK20785440.7T patent/DK3864053T3/da active
- 2020-09-10 CA CA3150947A patent/CA3150947A1/en active Pending
- 2020-09-10 CN CN202410529206.7A patent/CN118436777A/zh active Pending
- 2020-09-10 AU AU2020344154A patent/AU2020344154A1/en active Pending
- 2020-09-10 KR KR1020227011366A patent/KR20220062025A/ko active Pending
- 2020-09-10 EP EP23183390.6A patent/EP4230655A3/en active Pending
- 2020-09-10 SI SI202030263T patent/SI3864053T1/sl unknown
- 2020-09-10 EP EP20785440.7A patent/EP3864053B1/en active Active
- 2020-09-10 FI FIEP20785440.7T patent/FI3864053T3/fi active
- 2020-09-10 CN CN202080064158.9A patent/CN114401742B/zh active Active
- 2020-09-10 CN CN202410529209.0A patent/CN118403156A/zh active Pending
-
2022
- 2022-02-14 IL IL290619A patent/IL290619A/en unknown
-
2025
- 2025-09-25 JP JP2025159217A patent/JP2026016387A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2957112T3 (es) | 2024-01-11 |
| IL290619A (en) | 2022-04-01 |
| EP3864053B1 (en) | 2023-07-05 |
| CN114401742B (zh) | 2024-05-24 |
| CN118436777A (zh) | 2024-08-06 |
| DK3864053T3 (da) | 2023-09-11 |
| CN118403156A (zh) | 2024-07-30 |
| CA3150947A1 (en) | 2021-03-18 |
| CN114401742A (zh) | 2022-04-26 |
| SI3864053T1 (sl) | 2023-12-29 |
| FI3864053T3 (fi) | 2023-09-13 |
| KR20220062025A (ko) | 2022-05-13 |
| EP4230655A3 (en) | 2023-11-01 |
| JP7794735B2 (ja) | 2026-01-06 |
| JP2026016387A (ja) | 2026-02-03 |
| EP4230655A2 (en) | 2023-08-23 |
| EP3864053A1 (en) | 2021-08-18 |
| AU2020344154A1 (en) | 2022-04-07 |
| US20220298253A1 (en) | 2022-09-22 |
| WO2021048280A1 (en) | 2021-03-18 |
| JP2022548575A (ja) | 2022-11-21 |
| LT3864053T (lt) | 2023-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003010A (es) | Tratamiento de la emr mediante cambio de terapia. | |
| BR112022000231A2 (pt) | Novos métodos | |
| MX2021002322A (es) | Nuevos metodos. | |
| DOP2019000241A (es) | ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| MX2021013974A (es) | Metodos, sistemas y dispositivos de seleccion de pacientes tl1a. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| MX2021011489A (es) | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. | |
| MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| AR065589A1 (es) | Prediccion de respuesta a un inhibidor her | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
| CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| MX2025013942A (es) | Anticuerpos contra mucina 16 y metodos de uso de los mismos | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| BR112017022653A2 (pt) | ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph? | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. |